Amunix
Amunix, headquartered in South San Francisco, CA, develops conditionally active T cell engagers and cytokine therapies for cancer treatment using its PRO-XTEN technology platform. Acquired by Sanofi in February 2022, the company focuses on immuno-oncology to improve the therapeutic index of T cell engagers and cytokines.
Services
Amunix specializes in the development of conditionally active T cell engagers and cytokine therapies aimed at cancer treatment. The company utilizes its proprietary PRO-XTEN technology platform to create and refine these therapies. This technology allows for the preferential activation of drugs within tumor environments, significantly reducing off-tumor toxicity and improving patient tolerability. Amunix's core offerings include XPAT and XPAC proteins, which are designed to be activated specifically within the tumor microenvironment to target cancer cells more effectively.
Products
Amunix offers advanced therapeutic products focused on immuno-oncology. Their primary products include XPAT and XPAC proteins. XPAT proteins are engineered to minimize T cell-mediated cytotoxicity to improve tolerability. XPAC proteins are designed for use either as monotherapy or potentially in combination with other treatments like checkpoint inhibitors. These products leverage the company's PRO-XTEN technology for preferential activation in tumor environments, reducing off-tumor toxicity and enhancing therapeutic efficiency.
Technology Platform
Amunix's PRO-XTEN technology platform is central to its drug discovery and development efforts. This platform enables the development of conditionally active biologic therapies that are only activated within tumor microenvironments. This targeted approach helps in reducing off-tumor toxicity, thereby expanding the therapeutic index of T cell engagers and cytokines. The PRO-XTEN technology has been clinically validated and has been used in treatments involving over 200 patients, demonstrating its effectiveness and potential in cancer therapy.
Headquarters
Amunix is headquartered in South San Francisco, California. This location is a strategic hub for biotechnology companies, offering access to a rich network of industry experts and resources that support its research and development initiatives. The headquarters serve as the central point for Amunix's operations, including its technological development, research activities, and corporate management.
Acquisition by Sanofi
In February 2022, Amunix was acquired by Sanofi. This acquisition is part of Sanofi’s strategy to expand its immuno-oncology pipeline and leverage Amunix's innovative PRO-XTEN technology for developing next-generation cancer therapies. This strategic move aims to enhance Sanofi’s capabilities in producing conditionally active biological drugs that offer improved safety and efficacy profiles.